EA201100125A1 - Производные пирролопиридинилпиримидин-2-иламина - Google Patents

Производные пирролопиридинилпиримидин-2-иламина

Info

Publication number
EA201100125A1
EA201100125A1 EA201100125A EA201100125A EA201100125A1 EA 201100125 A1 EA201100125 A1 EA 201100125A1 EA 201100125 A EA201100125 A EA 201100125A EA 201100125 A EA201100125 A EA 201100125A EA 201100125 A1 EA201100125 A1 EA 201100125A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrropolypridinylpyrimidin
ilamine
derivatives
inhibitors
compounds
Prior art date
Application number
EA201100125A
Other languages
English (en)
Inventor
Маргарита Вухерер-Плиткер
Давид Брюже
Дирк Финзингер
Ульрих Грэдлер
Дитер Дорш
Кристина Эсдар
Original Assignee
Мерк Патент Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Патент Гмбх filed Critical Мерк Патент Гмбх
Publication of EA201100125A1 publication Critical patent/EA201100125A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Соединения формулы Iв которой X, R, R, R, Rи Rимеют значения, указанные в п.1, являются ингибиторами пролиферации клеток/жизнеспособности клеток и могут применяться для лечения опухолей.
EA201100125A 2008-07-03 2009-06-04 Производные пирролопиридинилпиримидин-2-иламина EA201100125A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102008031517A DE102008031517A1 (de) 2008-07-03 2008-07-03 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
PCT/EP2009/004013 WO2010000364A1 (de) 2008-07-03 2009-06-04 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate

Publications (1)

Publication Number Publication Date
EA201100125A1 true EA201100125A1 (ru) 2011-08-30

Family

ID=40849173

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100125A EA201100125A1 (ru) 2008-07-03 2009-06-04 Производные пирролопиридинилпиримидин-2-иламина

Country Status (16)

Country Link
US (1) US8420820B2 (ru)
EP (1) EP2291375B1 (ru)
JP (2) JP5587874B2 (ru)
KR (1) KR20110027835A (ru)
CN (1) CN102056926B (ru)
AR (1) AR072792A1 (ru)
AU (1) AU2009266090B2 (ru)
BR (1) BRPI0913832A2 (ru)
CA (1) CA2729725C (ru)
DE (1) DE102008031517A1 (ru)
EA (1) EA201100125A1 (ru)
ES (1) ES2564204T3 (ru)
IL (1) IL210406A (ru)
MX (1) MX2010013919A (ru)
WO (1) WO2010000364A1 (ru)
ZA (1) ZA201100876B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788659C2 (ru) * 2017-08-23 2023-01-24 Спринт Биосайенс Аб Азаиндолилпиридоны и диазаиндолилпиридоны

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
DE102009060174A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
JP5911470B2 (ja) 2010-04-16 2016-04-27 エーシー・イミューン・エス・アー アミロイドまたはアミロイド様タンパク質と関連する疾患を治療するための新規化合物
MX2012013196A (es) 2010-05-12 2013-03-22 Abbvie Inc Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.
DE102010050558A1 (de) 2010-11-05 2012-05-10 Merck Patent Gmbh 1H-Pyrrolo[2,3-b]pyridinderivate
DE102010053347A1 (de) * 2010-12-03 2012-06-06 Merck Patent Gmbh 3-Hetaryl-substituierte Pyrrolo[2,3-b] pyridin-derivative als PDK1-Inhibitoren
DE102011009961A1 (de) * 2011-02-01 2012-08-02 Merck Patent Gmbh 7-Azaindolderivate
DE102011105469A1 (de) * 2011-06-24 2012-12-27 Merck Patent Gmbh 7-Azaindolderivate
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
MX2015012456A (es) 2013-03-15 2016-02-03 Plexxikon Inc Compuestos heterociclicos y usos de los mismos.
CA2933767C (en) 2013-12-17 2018-11-06 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
EP3247353A4 (en) * 2015-01-23 2018-07-04 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN106432246B (zh) * 2015-08-05 2020-07-07 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN108137586B (zh) 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
GB201517217D0 (en) 2015-09-29 2015-11-11 Astex Therapeutics Ltd And Cancer Res Technology Ltd Pharmaceutical compounds
GB201704965D0 (en) * 2017-03-28 2017-05-10 Astex Therapeutics Ltd Pharmaceutical compounds
EP3694855A1 (en) 2017-10-13 2020-08-19 Plexxikon Inc. Solid forms of a compound for modulating kinases
WO2019086726A1 (es) 2017-10-31 2019-05-09 Alise Devices, S.L. Método de fabricación de elementos ópticos de seguridad documental personalizados y elemento obtenido
JP7018333B2 (ja) 2018-03-08 2022-02-10 大林道路株式会社 複装式カッター
CN112236428A (zh) 2018-04-24 2021-01-15 默克专利股份有限公司 抗增殖化合物及其用途
WO2020102686A1 (en) * 2018-11-16 2020-05-22 California Institute Of Technology Erk inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP2332940B1 (en) * 2004-03-30 2012-10-31 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of JAK and other protein kinases
DE602006014540D1 (en) 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102007028515A1 (de) * 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788659C2 (ru) * 2017-08-23 2023-01-24 Спринт Биосайенс Аб Азаиндолилпиридоны и диазаиндолилпиридоны

Also Published As

Publication number Publication date
ZA201100876B (en) 2011-10-26
AR072792A1 (es) 2010-09-22
CN102056926A (zh) 2011-05-11
ES2564204T3 (es) 2016-03-18
WO2010000364A8 (de) 2011-01-06
EP2291375B1 (de) 2016-01-06
CN102056926B (zh) 2013-10-16
JP5587874B2 (ja) 2014-09-10
CA2729725C (en) 2016-11-08
IL210406A0 (en) 2011-03-31
JP2011526260A (ja) 2011-10-06
AU2009266090B2 (en) 2014-04-03
JP5955902B2 (ja) 2016-07-20
KR20110027835A (ko) 2011-03-16
BRPI0913832A2 (pt) 2015-10-20
DE102008031517A1 (de) 2010-01-07
US8420820B2 (en) 2013-04-16
IL210406A (en) 2014-11-30
MX2010013919A (es) 2011-02-21
US20110218198A1 (en) 2011-09-08
WO2010000364A1 (de) 2010-01-07
JP2014240397A (ja) 2014-12-25
CA2729725A1 (en) 2010-01-07
EP2291375A1 (de) 2011-03-09
AU2009266090A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
EA201100125A1 (ru) Производные пирролопиридинилпиримидин-2-иламина
EA201300873A1 (ru) Производные 7-азаиндола
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201000004A1 (ru) Производные 6-(пирролопиридинил)пиримидин-2-иламина и их применение для лечения злокачественного новообразования и спида
EA201101399A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
EA201101585A1 (ru) 3-(1,2,3-триазол-4-ил)пирроло[2,3-b]пиридинпроизводные
EA201300442A1 (ru) ПИРРОЛИДИНОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ MetAP-2
EA201000094A1 (ru) Производные пиримидинил-пиридазинона
EA201200653A1 (ru) Гетариламинохинолины
EA201201170A1 (ru) Гетариламинонафтиридины
EA201401081A1 (ru) Циклические амиды в качестве ингибиторов метар-2
EA201100966A1 (ru) Производные пиридазинона
EA201000558A1 (ru) Производные имидазола
EA201400333A1 (ru) Бензонитрильные производные в качестве ингибиторов киназ
EA201001005A1 (ru) Производные 2-бензилпиридазинона в качестве ингибиторов мет киназы
EA201170051A1 (ru) Гетероциклическое соединение и его применение
EA201201081A1 (ru) Производные гетарил[1,8]нафтиридина
EA201000549A1 (ru) Производные пиперидина и пиперазина
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
EA201300282A1 (ru) Производные триазолопиразина
EA201291356A1 (ru) Пиперидиноновые производные как ингибиторы mdm2 для лечения рака
EA201001648A1 (ru) Производные пиридазинона